To allow for timely recruitment into clinical trials, new “onset-predictive” biomarker tests (OPBTs) like neurofilament light chain (NfL) are being developed to detect changes in carriers of pathogenetic variants in genes causing genetic FTD a few years before the onset of symptoms [6–8]. The gene discussed is NEFL; the disease is frontotemporal dementia.